These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36160794)

  • 1. Successful hematopoietic stem cell transplantation for two patients with relapse of intrachromosomal amplification of chromosome 21-positive B-cell precursor acute lymphoblastic leukemia.
    Harada T; Toyoda H; Tsuboya N; Hanaki R; Amano K; Hirayama M
    Front Pediatr; 2022; 10():960126. PubMed ID: 36160794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
    Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
    J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
    Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
    Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
    Heerema NA; Carroll AJ; Devidas M; Loh ML; Borowitz MJ; Gastier-Foster JM; Larsen EC; Mattano LA; Maloney KW; Willman CL; Wood BL; Winick NJ; Carroll WL; Hunger SP; Raetz EA
    J Clin Oncol; 2013 Sep; 31(27):3397-402. PubMed ID: 23940221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrachromosomal amplification of chromosome 21 in Korean pediatric patients with B-cell precursor acute lymphoblastic leukemia in a single institution.
    Yang M; Yi ES; Kim HJ; Yoo KH; Koo HH; Kim SH
    Blood Res; 2017 Jun; 52(2):100-105. PubMed ID: 28698845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrachromosomal Amplification of Chromosome 21 in Childhood Acute Lymphoblastic Leukemia: Study of 3 Cases.
    Mroczkowska A; Lejman M
    Case Rep Oncol; 2021; 14(1):592-598. PubMed ID: 33976639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
    Moorman AV; Robinson H; Schwab C; Richards SM; Hancock J; Mitchell CD; Goulden N; Vora A; Harrison CJ
    J Clin Oncol; 2013 Sep; 31(27):3389-96. PubMed ID: 23940220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).
    Moorman AV; Richards SM; Robinson HM; Strefford JC; Gibson BE; Kinsey SE; Eden TO; Vora AJ; Mitchell CD; Harrison CJ;
    Blood; 2007 Mar; 109(6):2327-30. PubMed ID: 17095619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia.
    Ivanov Öfverholm I; Zachariadis V; Taylan F; Marincevic-Zuniga Y; Tran AN; Saft L; Nilsson D; Syvänen AC; Lönnerholm G; Harila-Saari A; Nordenskjöld M; Heyman M; Nordgren A; Nordlund J; Barbany G
    Leuk Lymphoma; 2020 Mar; 61(3):604-613. PubMed ID: 31640433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
    Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
    J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
    Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
    Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
    Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of multiplex ligation dependent probe amplification (MLPA) for identification of acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21 (iAMP21) in a Brazilian population.
    Fuka G; Farias-Vieira TM; Hummel L; Blunck CB; Santoro JC; Terra-Granado E; Barbosa TC; Emerenciano M; Pombo-de-Oliveira MS
    Mol Cytogenet; 2015; 8():35. PubMed ID: 26060508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
    Zak T; Gao J; Behdad A; Mehta J; Altman JK; Ji P; Lu X; Sukhanova M
    Leuk Lymphoma; 2022 Dec; 63(13):3200-3207. PubMed ID: 35995457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.